<DOC>
	<DOCNO>NCT02271295</DOCNO>
	<brief_summary>Thrombosis occur small intrahepatic , well large vessel involve progression cirrhosis . Anticoagulation could reduce morbidity mortality cirrhotic patient</brief_summary>
	<brief_title>Impact Morbidity Mortality Prophylactic Dosing Low Molecular Weight Heparin Child-Pugh B Cirrhotic Patients : Randomized Controlled Study</brief_title>
	<detailed_description>Cirrhosis end-stage chronic liver disease . Cirrhosis critical step natural history liver disease , associate occurrence complication ( so-called decompensation ) death . Life expectancy vary 12-14 year patient compensate cirrhosis , 2-4 year decompensation . Cirrhosis associate thrombosis intrahepatic portal hepatic venous system lead parenchymal extinction ( atrophy ) , liver dysfunction portal hypertension . Regeneration area without microthrombosis , inflammation powerful factor induce liver cancer . Portal hepatic venous thrombosis show participate remodel liver architecture associate worsen outcome . Thrombosis cirrhosis think result procoagulant state due imbalance pro anticoagulant factor plasma level , inflammation around blood vessel , mark slow venous blood flow . Heparin administration , animal model liver fibrosis , decrease extra cellular matrix protein synthesis fibrous tissue deposition . Recently , reduction liver decompensation mortality show Child-Pugh B7-C10 cirrhotic patient assign receive low dose enoxaparin ( 4000IU/d ) , low molecular weight heparin , 48 week , compare patient receive anticoagulation therapy . These result line hypothesis protective role anticoagulation liver disease progression strong association thrombosis liver fibrosis . So main objective study compare effect 2-year low dose Enoxaparin ( 4000 IU/day ) versus treatment morbidity mortality patient Child B7-C10 cirrhosis .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Age ≥18 ≤75 year old A diagnosis cirrhosis base liver biopsy combination clinical , laboratory image criterion Compensated ChildPugh B7C10 Any follow causal factor : past control excessive alcohol intake ( &lt; 30g/d men &lt; 20g/d woman ) , HCV infection without viral replication , HBV infection without viral replication therapy , metabolic syndrome , biliary cirrhosis , autoimmune cirrhosis , hemochromatosis , cryptogenetic cirrhosis Ascites , portal hypertensive bleeding encephalopathy within last 3 month prior enrolment Hepatocellular carcinoma non consider remission Budd Chiari syndrome non consider remission Liver transplantation F2 F3 varix without treatment accordance recommend guideline ( Bblockers , ligation ) Portal vein thrombosis Transjugular intrahepatic portosystemic shunt Known extrahepatic malignancy PT &lt; 35 % Platelet count &lt; 50,000/mm3 Haemoglobin level &lt; 9g/dl Serum Albumin &lt; 20g/L A bone mineral density T score le 4.0 lumbar spine total hip Known HIV infection Ongoing anticoagulation antiaggregation Renal insufficiency define creatinine clearance &lt; 60ml/mn Conditions risk spontaneous bleeding ( except portal hypertension ) hemostatic abnormality relate cirrhosis Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Cirrhosis</keyword>
	<keyword>Child B</keyword>
	<keyword>decompensation</keyword>
	<keyword>mortality</keyword>
	<keyword>portal thrombosis</keyword>
	<keyword>anticoagulation</keyword>
</DOC>